 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2022, vol. 28, issue4
Subject Area: Medicine
-
DOI: 10.5272/jimab.2022284.4731
Published online: 13 December 2022
Original article
J of IMAB. 2022 Oct-Dec;28(4):4731-4734
BONE RESORPTION MARKER BETA-CROSSLAPS FOR EARLY MONITORING OF OSTEOPOROSIS TREATMENT WITH DENOSUMAB
Tatyana Simeonova1
, Krasimira Stefanova2, Pavlina Yordanova-Laleva3, Boryana Ruseva1, Aneliya Dimitrova1,
1) Department of Physiology and Pathophysiology, Medical University - Pleven, Bulgaria.
2) Diagnostic Consulting Center II - Pleven, Bulgaria.
3) Faculty of Pharmacy, Medical University-Pleven, Bulgaria.
ABSTRACT:
Antiresorptive long-term treatment for osteoporosis increases bone mineral density. Due to the long duration, poor compliance of patients to medication therapy is a big challenge. Bone mineral density measurements are recommended for the monitoring of treatment, but detectable changes may take up to 2-3 years. Bone turnover markers can indicate changes in bone turnover rates earlier, and assessment their levels may be effective in enhancing compliance and clinical efficacy.
Purpose: Our study aimed to assess whether the dynamics in serum levels of bone resorption marker beta-CrossLaps have a real practical benefit for early monitoring of postmenopausal osteoporosis treatment.
Materials and methods: 21 Bulgarian women in menopause with newly diagnosed osteoporosis were studied. All participants hadn’t been under treatment. Serum beta-CrossLaps levels were measured before and six months after subcutaneous administration of Denosumab – Injection 60 mg.
Results: Serum concentrations before and six months after starting treatment were respectively 0.589 ± 0.266 ng/ml (0.06 – 1.2) and 0.166 ± 0.139 ng/ml (0.05 – 0.59). The beta-CrossLaps pre-treatment serum levels were within the reference range for the commercial kit used. After six months of treatment, there was a significant decrease in serum concentrations of about 72% from baseline. In our study, although pre-treatment levels were within the reference range, a significant decrease in concentrations was observed.
Conclusions: The results show that the dynamics of beta-CrossLaps may be useful in the early monitoring of osteoporosis treatment.
Keywords: postmenopausal osteoporosis, early monitoring treatment, beta-CrossLaps, bone resorption markers, Denosumab,
- Download FULL TEXT /PDF 539 KB/
Please cite this article as: Simeonova T, Stefanova K, Yordanova-Laleva P, Ruseva B, Dimitrova A. Bone resorption marker Beta-CrossLaps for early monitoring of osteoporosis treatment with Denosumab. J of IMAB. 2022 Oct-Dec;28(4):4731-4734. DOI: 10.5272/jimab.2022284.4731
Correspondence to: Tatyana N. Simeonova, Department of Physiology and Pathological Physiology, Medical University-Pleven; 1, St. Kliment Ohridski str., Pleven 5800, Bulgaria; E-mail: dr_tsimeonova@abv.bg
REFERENCES:
1. Tan RZ, Loh TP, Vasikaran S. Bone turnover marker monitoring in osteoporosis treatment response. Eur J Endocrinol. 2020 Jul 1;183(1):C5-C7. [PubMed]
2. Vasikaran S. Assessment of bone turnover in osteoporosis: harmonization of the total testing process. Clin Chem Lab Med. 2018 Sep 25;56(10):1603-7. [PubMed]
3. Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clin Chem< Lab Med. 2011 Aug 1;49(8):1271-4. [PubMed]
4. Kanis JA, Cooper C, Rizzoli R, Reginster JY, ESCEO, IOF. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan;30(1):3-44. [PubMed]
5. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. [PubMed]
6. Zhang N, Zhang ZK, Yu Y, Zhuo Z, Zhang G, Zhang BT. Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. Front Cell Dev Biol. 2020 May 14;8:325. [PubMed]
7. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem. 2001 Apr 1;47(4):694-702. [PubMed]
8. Williams C, Sapra A. Osteoporosis Markers. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Jan 2022. [PubMed]
9. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. Potential utility of high preoperative levels of serum type i collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-termvariations after parathyroidectomy. J Bone Miner Metab. 2009 Mar;27(2):240-6. [PubMed]
10. Martínez J, Olmos JM, Hernández JL, Pinedo G, Llorca J, Obregón E, et al. Bone turnover markers in Spanish postmenopausal women. The Camargo cohort study. ClinChimActa. 2009 Nov 3;409(1-2):70-4. [PubMed]
11. Trento LK, Pietropolli A, Ticconi C, Gravotta E, De Martino MU, Fabbri A, et al. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women. J Obstet Gynaecol Res. 2009 Feb;35(1):152-9. [PubMed]
12. Reginster J-Y, Henrotin Y, Christiansen C, Gamwell-Henriksen E, Bruyere O, Collette J, et al. Bone Resorption in Post-menopausal Women with Normal and Low BMD Assessed with Biochemical Markers Specific for Telopeptide Derived Degradation Products of Collagen Type I. Calcif Tissue Int. 2001Sep;69(3):130-7. [PubMed]
13. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996 Mar;11(3):337-9. [PubMed]
14. Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NFA, McCloskey EV, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016 Jan;27(1):21-31. [PubMed]
15. Naeem ST, Hussain R, Raheem A, Siddiqui I, Ghani F, Khan AH. Bone turnover markers for osteoporosis status assessment at baseline in postmenopausal Pakistani females. J Coll Physicians Surg Pakistan. 2016 May 1;26(5):408-12. [PubMed]
16. Lorentzon M, Branco J, Brandi ML, Bruyère O, Chapurlat R, Cooper C, et al. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. AdvTher. 2019Oct 1;36(10):2811-24. [PubMed]
17. ParkSY, Ahn SH, Yoo JI, Chung YJ, Jeon YK, Yoon BH, et al. Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment. J Bone Metab. 2019 Nov;26(4):213-24. [PubMed]
18. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011 Mar;26(3):530-7. [PubMed]
19. Aslan M, Çöğendez E, Eken M, Arıoglu P, Eren S. SERUM BETA CROSSLAPS AS A PREDICTOR FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN. Journal of Istanbul Faculty of Medicine. 2015 Aug;78(2):36-40. [Crossref]
20. Bulgarian Society of Endocrinology. [Recommendations for good clinical practice in osteoporosis.] [in Bulgarian] Ministry of Healthcare, Sofia. 2019: pp. 56-57. [Internet].
Received: 10 June 2022
Published online: 13 December 2022